NCT07210294 Press Needle on Body Acupuncture Points and Auricular Acupuncture Points on Functional Dyspepsia
| NCT ID | NCT07210294 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitas Indonesia |
| Condition | Functional Dyspepsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2025-08-28 |
| Primary Completion | 2026-07-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2025-08-28 with a primary completion date of 2026-07-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study was to prove that press needle (PN) and medication are more effective in reducing symptoms and improving quality of life in people with functional dyspepsia compared to sham press needle (Sham PN) and medication. The main questions this study aims to answer are: * Does the press needle and medication group reduce symptoms in people with functional dyspepsia as assessed by the Short Form-Leeds Dyspepsia Questionnaire (SF-LDQ) compared to the sham press-needle and medication group on days 7 and 14, compared to before therapy? * Does the press-needle and medication group improve quality of life in people with functional dyspepsia as assessed by the Short-Form Nepean Dyspepsia Index (SF-NDI) compared to the sham press-needle and medication group on days 7 and 14, compared to before therapy? A total of 38 participants were randomly allocated into two groups, either PN or Sham PN needle groups Participants will: * Receive PN or Sham PN for 14 days and replaced on day 7. * Complete the SF-LDQ and SF-NDI questionnaires before therapy, on day 7, and day 14.
Eligibility Criteria
Inclusion Criteria: * Male or female aged 18-59 years * Patients with functional dyspepsia * Esophagogastroduodenoscopy (EGD) results show no significant structural abnormalities or no structural abnormalities. * Willing to participate in the research until completion and sign a letter of consent for medical action (informed consent). Exclusion Criteria: * At the acupuncture point location there is inflammation, malignancy, and scar tissue. * Deformity of the earlobe. * History of allergies to stainless steel and plaster. * Medical emergencies, impaired consciousness, pregnancy, history of diabetes mellitus, and history of keloid formation. * History of digestive tract cancer, history of hepatobiliary cancer, history of chronic kidney failure stage 4 and 5, history of hyperthyroidism or hypothyroidism.
Contact & Investigator
KPEK FKUI-RSCM
PRINCIPAL INVESTIGATOR
The Health Research Ethics Commitee - Faculty of Medicine Universitas Indonesia and Dr. Cipto Mangunkusumo National Hospital
Frequently Asked Questions
Who can join the NCT07210294 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 59 Years, studying Functional Dyspepsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07210294 currently recruiting?
Yes, NCT07210294 is actively recruiting participants. Contact the research team at maria.darmawan@gmail.com for enrollment information.
Where is the NCT07210294 trial being conducted?
This trial is being conducted at Jakarta Pusat, Indonesia.
Who is sponsoring the NCT07210294 clinical trial?
NCT07210294 is sponsored by Universitas Indonesia. The principal investigator is KPEK FKUI-RSCM at The Health Research Ethics Commitee - Faculty of Medicine Universitas Indonesia and Dr. Cipto Mangunkusumo National Hospital. The trial plans to enroll 38 participants.